344 related articles for article (PubMed ID: 15827057)
1. Follow-on biologics: challenges of the "next generation".
Schellekens H
Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv31-36. PubMed ID: 15827057
[TBL] [Abstract][Full Text] [Related]
2. Biosimilars: it's not as simple as cost alone.
Roger SD; Goldsmith D
J Clin Pharm Ther; 2008 Oct; 33(5):459-64. PubMed ID: 18834359
[TBL] [Abstract][Full Text] [Related]
3. Biosimilars: how similar or dissimilar are they?
Roger SD
Nephrology (Carlton); 2006 Aug; 11(4):341-6. PubMed ID: 16889575
[TBL] [Abstract][Full Text] [Related]
4. Antibody-mediated pure red cell aplasia (PRCA): epidemiology, immunogenicity and risks.
Macdougall IC
Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv9-15. PubMed ID: 15827058
[TBL] [Abstract][Full Text] [Related]
5. European regulatory guidelines for biosimilars.
Wiecek A; Mikhail A
Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v17-20. PubMed ID: 16959790
[TBL] [Abstract][Full Text] [Related]
6. Statistical assessment of biosimilar products.
Chow SC; Liu JP
J Biopharm Stat; 2010 Jan; 20(1):10-30. PubMed ID: 20077246
[TBL] [Abstract][Full Text] [Related]
7. Biosimilar epoetins and other "follow-on" biologics: update on the European experiences.
Jelkmann W
Am J Hematol; 2010 Oct; 85(10):771-80. PubMed ID: 20706990
[TBL] [Abstract][Full Text] [Related]
8. Comparative testing and pharmacovigilance of biosimilars.
Locatelli F; Roger S
Nephrol Dial Transplant; 2006 Oct; 21 Suppl 5():v13-6. PubMed ID: 16959789
[TBL] [Abstract][Full Text] [Related]
9. Recommendations regarding technical standards for follow-on biologics: comparability, similarity, interchangeability.
Davis GC; Beals JM; Johnson C; Mayer MH; Meiklejohn BI; Mitlak BH; Roth JL; Towns JK; Veenhuizen M
Curr Med Res Opin; 2009 Jul; 25(7):1655-61. PubMed ID: 19476407
[TBL] [Abstract][Full Text] [Related]
10. What is antibody-mediated pure red cell aplasia (PRCA)?
Casadevall N
Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv3-8. PubMed ID: 15827056
[TBL] [Abstract][Full Text] [Related]
11. The challenge of follow-on biologics for treatment of multiple sclerosis.
Reingold SC; Steiner JP; Polman CH; Cohen JA; Freedman MS; Kappos L; Thompson AJ; Wolinsky JS
Neurology; 2009 Aug; 73(7):552-9. PubMed ID: 19687456
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars approval process.
Zuñiga L; Calvo B
Regul Toxicol Pharmacol; 2010 Apr; 56(3):374-7. PubMed ID: 19925842
[TBL] [Abstract][Full Text] [Related]
13. Biosimilars: current status and future directions.
Roger SD
Expert Opin Biol Ther; 2010 Jul; 10(7):1011-8. PubMed ID: 20384525
[TBL] [Abstract][Full Text] [Related]
14. Biosimilars: pharmacovigilance and risk management.
Zuñiga L; Calvo B
Pharmacoepidemiol Drug Saf; 2010 Jul; 19(7):661-9. PubMed ID: 20583204
[TBL] [Abstract][Full Text] [Related]
15. Basic facts about biosimilars.
Nowicki M
Kidney Blood Press Res; 2007; 30(5):267-72. PubMed ID: 17622764
[TBL] [Abstract][Full Text] [Related]
16. Assessing the bioequivalence of biosimilars The Retacrit case.
Schellekens H
Drug Discov Today; 2009 May; 14(9-10):495-9. PubMed ID: 19429509
[TBL] [Abstract][Full Text] [Related]
17. [Position statements regarding usage of biosimilars of Epoetins. Position paper of the Société de néphrologie, Société francophone de dialyse, and Société de néphrologie pédiatrique].
Bouchet JL; Brunet P; Canaud B; Chanliau J; Combe C; Deray G; Houillier P; Kourilsky O; Ledneva E; Niaudet P; Ortiz JP; Pavlovic M; Ryckelynck JP; Singlas E; Verhelst D; ; ;
Nephrol Ther; 2009 Feb; 5(1):61-6. PubMed ID: 19084489
[TBL] [Abstract][Full Text] [Related]
18. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Ahmed I; Kaspar B; Sharma U
Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of erythropoietin-associated pure red cell aplasia.
Carson KR; Evens AM; Bennett CL; Luminari S
Best Pract Res Clin Haematol; 2005; 18(3):467-72. PubMed ID: 15792921
[TBL] [Abstract][Full Text] [Related]
20. Assays for detecting and diagnosing antibody-mediated pure red cell aplasia (PRCA): an assessment of available procedures.
Thorpe R; Swanson SJ
Nephrol Dial Transplant; 2005 May; 20 Suppl 4():iv16-22. PubMed ID: 15827053
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
